文献速递肾小球疾病

反对:IgA肾病中应停止免疫抑制治疗

Con: STOP immunosuppression in IgA nephropathy.
PubMed 文献 · Nephrol Dial Transplant · 2016-08-11

本文基于STOP-IgAN试验,该试验在高进展风险的IgA肾病患者中比较免疫抑制联合支持治疗与单纯支持治疗。免疫抑制组完全临床缓解率更高且蛋白尿一过性下降,但两组肾功能恶化均较既往研究显著缓慢,加用免疫抑制未进一步延缓肾功能恶化。

要点

  • 支持治疗是IgA肾病患者的主要治疗手段。
  • 免疫抑制联合支持治疗未进一步延缓高危患者的肾功能恶化。
  • 快速进展或持续蛋白尿>3.5 g/天的患者需进一步评估免疫抑制治疗的潜在获益。

核心结论

  • 在高进展风险的IgA肾病患者中,免疫抑制联合支持治疗虽提高完全临床缓解率并一过性降低蛋白尿,但未进一步延缓肾功能恶化。
  • 免疫抑制组观察到的蛋白尿一过性下降未转化为整体肾脏结局的改善。
  • 试验期间两组间eGFR变化趋势未见分歧迹象。
  • 快速进展和持续蛋白尿>3.5 g/天的IgA肾病患者需进一步评估免疫抑制治疗的潜在获益。

研究设计与样本

  • STOP-IgAN试验系统筛选高进展风险的IgA肾病患者,评估免疫抑制联合支持治疗对肾脏终点的影响。
  • 试验为期3年,肾脏功能恶化定义为eGFR下降至少15 mL/min的患者数。
  • 研究设有导入期,排除特定不常见患者组。

主要发现

  • 免疫抑制组完全临床缓解率更高,且出现一过性蛋白尿下降。
  • 两组肾功能恶化均较既往研究显著缓慢,加用免疫抑制未进一步延缓恶化。
  • 在随机患者中确认较低基线蛋白尿可预测IgA肾病临床缓解。
  • 免疫抑制组蛋白尿一过性下降未转化为整体肾脏结局改善。
  • 试验期间两组eGFR变化趋势未见分歧迹象。

临床怎么用

  • 作者认为,快速进展和持续蛋白尿>3.5 g/天的IgA肾病患者需进一步评估免疫抑制治疗的潜在获益。

局限性

  • 尽管更长时间随访是可取的,但试验期间两组eGFR变化趋势未见分歧迹象。
  • 导入期排除了特定不常见患者组,快速进展和持续蛋白尿>3.5 g/天的患者需进一步评估免疫抑制治疗的潜在获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A comprehensive supportive therapy approach constitutes the mainstay treatment of IgA nephropathy (IgAN) patients. In our recent Supportive versus immunosuppressive Therapy Of Progressive IgA Nephropathy (STOP-IgAN) trial, we systematically selected for patients at high risk of a progressive disease course and evaluated the effect of immunosuppression, combined with supportive care, on renal end points in these patients. There was a higher rate of full clinical remission and transient proteinuria reduction in immunosuppressed patients. However, deterioration of renal function (i.e. number of patients with an estimated glomerular filtration rate (eGFR) decrease of at least 15 mL/min over the 3-year trial phase) was remarkably slow in both groups, compared with previous studies, and was not slowed further by adding immunosuppression to supportive care. Here, we address several concerns raised on the design and interpretation of our trial. In our randomized patients, we confirmed a lower baseline proteinuria to be predictive of clinical remission in IgAN. However, the observed transient drop in proteinuria in the immunosuppressed patients did not translate into an improved overall renal outcome in these patients. Although longer follow-up would be desirable, there was not even a trend for the eGFR course to diverge between our two treatment arms during the trial phase. Finally, it is important to note that we excluded specific infrequent patient groups during our run-in phase. Therefore, IgAN patients with a rapidly progressing course and those with persistent proteinuria >3.5 g/day would require further evaluation regarding potential benefits of immunosuppressive therapies.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Rauen T, Eitner F, Fitzner C, et al. Con: STOP immunosuppression in IgA nephropathy. Nephrol Dial Transplant. 2016. PMID: 27515693

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。